----item----
version: 1
id: {B9D9C9DF-49A9-4096-98A3-F8B48972C82D}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/02/20/Ciba Vision Ophthalmics US and Quadra Logic Technologies Canada forge photodynamic therapy PDT agree
parent: {184B29B6-DEB4-4530-87D1-5027A0A492F2}
name: Ciba Vision Ophthalmics US and Quadra Logic Technologies Canada forge photodynamic therapy PDT agree
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: 99c0f48e-8e77-48b7-b6ce-02e722203a99

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 284

<p>Ciba Vision Ophthalmics (US) and Canadian company Quadra Logic Technologies will develop and commercialise photodynamic therapy (PDT) for treating eye disease. Ciba Vision will fund 60% of development costs while profits from sales of resulting products will be shared equally.</p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 110

Ciba Vision Ophthalmics (US) and Quadra Logic Technologies (Canada) forge photodynamic therapy (PDT) agreement
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1270

<p>Ciba Vision Ophthalmics (US) and Canadian company Quadra Logic Technologies will develop and commercialise photodynamic therapy (PDT) for treating eye disease. Ciba Vision will fund 60% of development costs while profits from sales of resulting products will be shared equally.</p><p>The first project will target age-related macular degeneration, a neovascular disease which is the leading cause of blindness in the elderly and affects seven million people in North America. Initially, the companies are targeting a particular form of AMD and have submitted Investigational New Drug Applications in the US and Germany for PDT using benzoporphyrin.</p><p>The agreement between Ciba Vision and Quadra Logic covers all potential applications of PDT. These include corneal neovascularisation, intra-ocular tumours and diabetic retinopathy. The companies will also evaluate other photosensitisers.</p><p>Quadra Logic is developing PDT products for treating conditions in other parts of the body. Photofrin was recommended for approval for oesophageal cancer by the FDA's oncologic drugs advisory committee in September (see Clinica No 621, p 20). The drug-device combination has already been approved for treating various cancers in the Netherlands, Japan and Canada.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 233

{DA44CA46-4196-4BEB-9C53-EC7BF60AB02C}|{B2967A9C-ABDA-4628-A672-9EDDCD142AEA}|{F5161CC2-772F-472E-A21C-BF196343462E}|{2360F67B-A7D7-4E2A-9C6C-5618FAE5CB5D}|{2E0CEEF8-031D-43E8-B6AA-07D1397D9E4F}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 100

Ciba Vision Ophthalmics US and Quadra Logic Technologies Canada forge photodynamic therapy PDT agree
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950220T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950220T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950220T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT051630
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 110

Ciba Vision Ophthalmics (US) and Quadra Logic Technologies (Canada) forge photodynamic therapy (PDT) agreement
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

253399
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T183921Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

99c0f48e-8e77-48b7-b6ce-02e722203a99
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T183921Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
